Provided are methods of treating skin cancer in an individual in need thereof by administering to the individual vismodegib and a replication-deficient type 5 adenovirus for expression of interferon gamma.

A chimeric antigen receptor includes a) an extracellular target molecule combination domain, used for a specific-binding target molecule; b) an intracellular signaling domain including at least one intracellular activation signaling domain and/or at least one intracellular detection signaling domain; and c) a transmembrane domain, used to connect the extracellular target molecule combination domain and the intracellular signaling domain, and fix the two domains on a cell membrane. Activation of the intracellular signaling domain at least relies on combination of the extracellular target molecule combination domain with the target molecule, and the intracellular activation signaling domain contains a molecule or a fragment having a catalytic functional group. The present chimeric antigen receptor combines various means to create and apply an artificial molecular machine, thus having the strengths of an immune checkpoint inhibitor and of cell therapy at the same time, and providing a solution for improving treatment of solid tumors.

Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

The technology described herein is directed to methods of treating and diagnosing cancer, e.g, by measuring the expression of certain genes in exosomes.

A method of forming an immunomodulatory implant operatively arranged to chemotactically facilitate bone morphogenesis, the method including forming a matrix of a first material, the matrix including an outer surface, and a plurality of pores, and applying an antigen to the matrix, wherein the antigen including at least one of a bacterial antigen or a viral antigen.

The present invention relates to the use of human anti-inflammatory peptides in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of vasoactive intestinal peptide, C-type natriuretic peptide, B-type natriuretic peptide, pituitary adenylate cyclase-activating peptide, adrenomedullin, alpha-melanocyte stimulating hormone, relaxin and Interferon gamma for said purposes. Advantageous features of an aerosol containing such a human anti-inflammatory peptide and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases. One aspect relates to treatment of CoViD-19 related ARDS.

The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutritive media up to about 72 hours. The storage method enables the cells to be manufactured at a processing facility and shipped to a point of care site. The invention also includes compositions that have been stored in non-nutritive buffer at storage temperatures while maintaining the functional characteristics.

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The present disclosure relates to methods of inducing tolerance to lung allograft transplantation. These methods comprise increasing suppressor CD8.sup.+ T cells and/or suppressing deleterious CD8+ and CD4.sup.+ T cells.

A composition and method for using a composition, the composition having at least two compounds, each of which induces indolamine 2,3-dioxygenase, for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the inducers have different mechanism of action and wherein the composition gives rise to a synergistic effect on the IDO levels.